From small steps to big leaps – 200 years of Parkinson’s disease research and therapy advancements
sponsored by BOSTON SCIENTIFIC
Author: SPONSOREDPublished: 20 September 2017
Prep: Cook: Serves:
Two hundred years after the symptoms of Parkinson’s were first identified, we talk to four world-renowned experts in Parkinson’s disease about how treatment of the condition has improved – and what the future will bring for people living with Parkinson’s
An essay that marked the beginning of Parkinson’s therapy Every story has a beginning and Parkinson’s disease is no different. Its story began 200 years ago, when an English surgeon, James Parkinson, made medical history with his simple but pioneering ‘Essay on the Shaking Palsy’, which described the symptoms of the disease for the first time.
Exponential growth in Parkinson’s research and therapies If Parkinson’s disease research progress were expressed in mathematical terms, it would resemble an exponential graph. At the beginning there seemed to be very little progress but over time a rapid increase in understanding of the mechanisms behind the disease emerged.
Professor Volkmann, a Parkinson’s expert from the University Clinic of Würzburg, Germany, explains how these leaps of understanding occurred: “After the initial description by James Parkinson, it took approximately another 100 years to completely understand the pathological lesions in the brain, then another 50 years for its biochemical base to be described, which led almost immediately to dopamine replacement therapy, one of the most effective treatments discovered.
“This neurotransmitter replacement paved the way for neurotransplantation, gene therapy and even brain pace making, known today as deep brain stimulation (DBS).”
Keeping the brain young and keeping disability at bay Professor Volkmann adds: “With DBS we now have a new concept which extends what we call the ‘honeymoon period’ – the time in which people with Parkinson’s are experiencing very little disability and can lead a normal life, with their job, family and daily activities – for as long as possible. As physicians this is one of our main goals.”
Research also shows the potential advantages of early treatment in keeping the brain younger for longer.
Professor Volkmann explains: “When a person is treated early, we see an effect on how the disease progresses, because if a person has good mobility and is living an almost normal and active life, it may have neuroprotective effects in the brain where impaired mobility and other symptoms of the disease are lessened. We have already seen the scientific evidence in animal models and the patients we see in our daily practice are living proof of it.”
Two paradigm shifts: resolving current challenges and opening up new frontiers in Parkinson’s research We’ve come a long way in treating Parkinson’s over the last two centuries, yet scientists are always challenging the status quo.
Professor Pollo from the University Hospital Bern, Switzerland, explains: “Parkinson’s is not only a motor disorder disease. The non-motor symptoms of Parkinson’s have been somewhat neglected in scientific research and development. With DBS, we are also exploring ways to improve cognition, depression, erectile dysfunction and other non-motor complications. We’re still in an experimental phase, but we see great potential in the technology which may have a huge impact in improving overall quality of life.”
Professor Lozano, a leading scientist from the University of Toronto, Canada, adds: “There are some features that respond very well to levodopa and/or to surgery, but other debilitating non-motor symptoms such as speech, cognitive disturbances, mood disorders, sexual problems and urinary dysfunction also need special attention.”
Parkinson’s disease belongs to the more developed conditions among neurodegenerative disorders in terms of our scientific understanding of its causes, progress and treatment.
DBS has been a proven option for the last 20 years. However, as Professor McIntyre from Case Western Reserve University School of Medicine, Cleveland, Ohio, US, reminds us: “DBS was pretty stagnant in the first 20 years of its clinical existence. The last three or four years, however, have brought new engineering developments in the devices with new electrode designs and new stimulation strategies. We are only starting to go down that road and it is exciting to think about how that technology is going to keep moving on.”
Professor Pollo explains that the introduction of directional steering – a new technology that allows for more precise stimulation in those targeted areas in the brain – brought about a paradigm shift.
“Before, the challenge in DBS was precision,” he says. “Without directional steering, stimulation could lead to stimulation-induced side effects. The advantage of the new steering technology is that it is more selective and much more precise, targeting only the areas we need to target and thereby avoiding side effects. This evolution of DBS technology addressed a major and unresolved challenge in Parkinson’s disease.”
The role of technology in the future of Parkinson’s care and individualised treatment An expert in biochemical engineering, Professor McIntyre offers his vision of future technologies in the treatment of Parkinson’s: “There are three main areas to watch for big improvements when it comes to DBS. The first one is in terms of hardware, where new developments in the design of the electrodes provide far more flexible and selective stimulation. Secondly, we see software improvements drive new clinical applications. These computational models are getting more real and detailed every year, making it easier to customise therapy to the needs of each individual patient, either by using imaging data or clinical outcomes data.
And lastly, wearable sensors and DBS. In the future these personal devices may feed information to the stimulation devices, allowing for the right therapy at the right time. This is something already being used in pain management with spinal cord stimulation.”
Parkinson’s disease at the forefront of neurodegenerative disorder research The scientific attention Parkinson’s disease has received over the past 200 years has been a door opener for research in other neurodegenerative disorders. As scientists garnered better understanding of the underlying mechanisms of the brain and technological systems such as DBS, they began to explore other areas where they could apply that learning.
Professor Lozano explains: “With our experience from Parkinson’s disease, we already have an understanding of the circuits of the brain that are malfunctioning, and so by using DBS we are able to modify their activity. We are now starting to look at diseases like Alzheimer’s and depression, for example, and how we can use the technology to benefit people affected by these diseases. The potential is huge and there’s an exciting scientific journey ahead of us.”
About deep brain stimulation (DBS) therapy
DBS uses a stimulator that is implanted into the patient’s chest. The stimulator sends mild electrical impulses to specific areas of the brain via thin wires called leads. This stimulation may help improve day-to-day experiences for people living with movement disorders such as Parkinson’s disease, dystonia, or essential tremor.
For comprehensive information on deep brain stimulation and Parkinson’s, please visit the EPDA website.
This article is sponsored by Boston Scientific. The information in this article is given for information purposes only and does not represent an endorsement by the EPDA of any particular treatments, products or companies. This article is not a substitute for advice from your doctor, pharmacist or other healthcare professional. Parkinson’s Life makes no representations or warranties of any kind, express or implied, about the completeness or accuracy of information provided.
Parkinson’s podcast: ‘New Neurons for Old’ – interview with Dr Roger Barker
The controversial history of foetal tissue and stem cell therapies
1 day ago
Study suggests why neurons die in Parkinson’s disease
Researchers at the University of Córdoba, Spain, have discovered how a certain protein may be linked to death of dopamine-producing neurons associated with Parkinson’s. Using animal models of the condition to conduct their study, the team focused on the protein DJ-1 – whose link to Parkinson’s has previously been established, though its exact function was uncertain. The researchers compared neurons in the brains of mice that possessed the gene expressing DJ-1 with those that did not. The findings revealed that dysfunction or absence of the gene expressing the DJ-1 protein could trigger the ‘cell cycle’ (the process by which cells divide), which should not occur under normal conditions. Because neurons lack the capacity to divide, this causes them die – leading to the onset of symptoms linked with Parkinson’s. It is hoped that uncovering these details about the relationship between DJ-1’s absence and Parkinson’s may lead to the development of…
Researchers have finally identified brain cells linked to Parkinson’s disease
For decades, scientists have known that Parkinson’s is associated with the death of dopamine-producing cells in the brain. Now, researchers from the Broad Institute of MIT and Harvard, US, have discovered the specific subtype of brain cells that die in Parkinson’s disease. Using a technique called single-cell RNA signalling, which enables the individual analysis of cells within a tissue for activity and protein production, researchers identified 10 subtypes of dopamine-producing cells within the donated brains of people who died from causes unrelated to Parkinson’s. The team carried out the same investigation on people who had died with Parkinson’s or a condition with similar symptoms called Lewy body dementia. They discovered that only one subtype of the cells had reduced in number – which suggests many of these cells had died while the people were living. It is hoped that the findings could lead to better understanding of Parkinson’s causes and…
Tiny DBS implant shows potential to advance Parkinson’s disease treatment
In an innovative trial by North Bristol NHS Trust, UK, surgeons have succeeded in implanting a tiny deep brain stimulation (DBS) device into a person’s skull. Their aim? To address symptoms of Parkinson’s. Designed with a tiny battery system that is inserted into the skull, the DBS device delivers electric impulses to targeted areas of the brain through electric probes. In doing so, it works to address abnormal brain cell activity associated with Parkinson’s – and may help to ease symptoms. One of around 25 patients selected for the year-long trial has described the device’s impact as “amazing”. Commenting on the results of the trial so far, consultant neurologist Dr Alan Whone of North Bristol NHS Trust said: “We are hopeful that if these findings hold up, we will have a significant technical advance by which to improve Parkinson’s care across the world.”